The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies

Consortium of Metabolomics Studies, Bing Yu, Krista A Zanetti, Marinella Temprosa, Demetrius Albanes, Nathan Appel, Clara Barrios Barrera, Yoav Ben-shlomo, Eric Boerwinkle, Juan P. Casas, Clary Clish, Jacqueline Price

Research output: Contribution to journalArticlepeer-review


The Consortium of Metabolomics Studies (COMETS) was established in 2014 to facilitate large-scale collaborative research on the human metabolome and its relationship with disease etiology, diagnosis, and prognosis. COMETS comprised 47 cohorts from Asia, Europe, North America and South America that together include 137, 000+ participants with blood metabolomics data on samples collected from 1985 to 2017. Metabolomics data were provided by 17 different platforms with the most frequently used labs being Metabolon Inc. (14 cohorts), the Broad Institute (15 cohorts), and Nightingale Health (11 cohorts). Participants were followed for a median 23 years for health outcomes, including death, cancer, cardiovascular disease, diabetes and others. Available exposure-related data include common clinical measurements, behavioral factors, as well as genome-wide genotype data. Two feasibility studies were conducted to evaluate the comparability of metabolomics platforms used by COMETS cohorts. The first study showed that the overlap between any two different laboratories ranged from 6 to 121 metabolites at five leading laboratories. The second study showed that the median Spearman correlation comparing 111 overlapping metabolites captured by Metabolon and the Broad Institute was 0.79 (interquartile range, 0.56–0.89).
Original languageEnglish
JournalAmerican Journal of Epidemiology
Publication statusPublished - 19 Feb 2019


Dive into the research topics of 'The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies'. Together they form a unique fingerprint.

Cite this